ES2093361T3 - Tratamiento de enfermedades neurodegenerativas. - Google Patents

Tratamiento de enfermedades neurodegenerativas.

Info

Publication number
ES2093361T3
ES2093361T3 ES93301534T ES93301534T ES2093361T3 ES 2093361 T3 ES2093361 T3 ES 2093361T3 ES 93301534 T ES93301534 T ES 93301534T ES 93301534 T ES93301534 T ES 93301534T ES 2093361 T3 ES2093361 T3 ES 2093361T3
Authority
ES
Spain
Prior art keywords
treatment
neurodegenerative diseases
meta
neurodegenerative
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93301534T
Other languages
English (en)
Spanish (es)
Inventor
William S Caldwell
Patrick M Lippiello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RJ Reynolds Tobacco Co
Original Assignee
RJ Reynolds Tobacco Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RJ Reynolds Tobacco Co filed Critical RJ Reynolds Tobacco Co
Application granted granted Critical
Publication of ES2093361T3 publication Critical patent/ES2093361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
ES93301534T 1992-03-02 1993-03-01 Tratamiento de enfermedades neurodegenerativas. Expired - Lifetime ES2093361T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/844,364 US5212188A (en) 1992-03-02 1992-03-02 Method for treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ES2093361T3 true ES2093361T3 (es) 1996-12-16

Family

ID=25292523

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93301534T Expired - Lifetime ES2093361T3 (es) 1992-03-02 1993-03-01 Tratamiento de enfermedades neurodegenerativas.

Country Status (8)

Country Link
US (1) US5212188A (enExample)
EP (1) EP0559413B1 (enExample)
JP (1) JPH0624983A (enExample)
AT (1) ATE143263T1 (enExample)
DE (1) DE69304955T2 (enExample)
DK (1) DK0559413T3 (enExample)
ES (1) ES2093361T3 (enExample)
GR (1) GR3022072T3 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093869A1 (es) * 2000-06-05 2001-12-13 Benito Arranz Sanjuan Sildenafilo y nicotina, asociacion sinergica para las enfermedades neurodegenerativas

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
ATE334120T1 (de) * 1995-01-06 2006-08-15 Targacept Inc Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
US5731314A (en) * 1995-01-06 1998-03-24 Bencherif; Merouane Pharamceutical compositions for prevention and treatment of tourette's syndrome
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US6166048A (en) * 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
WO1997040011A1 (en) 1996-04-23 1997-10-30 R. J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US6531606B1 (en) * 1997-02-21 2003-03-11 Targacept, Inc. Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US7214686B2 (en) * 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
EP1056458B1 (en) * 1998-02-24 2005-04-27 Wake Forest University Treatment of chronic pain
EP1068186A2 (en) 1998-04-02 2001-01-17 Targacept, Inc. Pharmaceutical compositions and methods for use
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6262124B1 (en) * 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
CA2376061A1 (en) * 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US6890935B2 (en) * 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
US6852741B2 (en) 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US7074812B2 (en) * 2002-08-02 2006-07-11 Nutraleutical Development Corporation Development of muscle mass in a mammal
EP1678172B1 (en) * 2003-10-15 2009-12-09 Targacept, Inc. Azabicyclic compounds for relieving pain and treating central nervous system disorders
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
BRPI0418712B8 (pt) * 2004-04-02 2021-06-22 Arterial Remodelling Tech Inc método para preparar uma montagem para fornecimento de um stent polimérico degradável e bioreabsorvível, montagem para fornecer um stent degradável e bioreabsorvível e método para preparar um stent polimérico degradável e bioreabsorvível
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2021325A2 (en) * 2006-05-09 2009-02-11 AstraZeneca AB Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
AR062860A1 (es) * 2006-09-15 2008-12-10 Astrazeneca Ab Combinaciones terapeuticas 482
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
ES2521494T3 (es) * 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
BRPI0815070A2 (pt) * 2007-07-31 2018-07-31 Astrazeneca Ab Administração transdérmica de (2s)-(4e)-n-metil-5-(3- (5-isopropoxipiridin) il-4-penten-2-amina
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US11219627B2 (en) * 2014-05-16 2022-01-11 Synaptec Development Llc Clearance of amyloid beta
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870794A (en) * 1974-02-20 1975-03-11 Foundation For Behavioral Rese Treatment of certain emotional disorders with nicotine compounds
HU179164B (en) * 1979-12-14 1982-08-28 Egyt Gyogyszervegyeszeti Gyar Process for producing cycloalkyl-ethers of alkanolamines
US4442292A (en) * 1981-01-29 1984-04-10 Philip Morris Incorporated Optically active nicotine analogs and process for their preparation
US4578394A (en) * 1984-12-10 1986-03-25 Hoechst-Roussel Pharmaceuticals Incorporated Cholinergic function increasing 3-[N-(pyridyl) carbamoyl]-1,4-dihydropyridines
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4863930A (en) * 1986-12-19 1989-09-05 Adhikary Parimal K Use of substituted 5H-pyrido- and 5H-thiazolo(2',1':2,3)imidazo (4,5-b)indoles as cholinomimetic agents
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5015741A (en) * 1989-10-03 1991-05-14 Philip Morris Incorporated Nicotine analogs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093869A1 (es) * 2000-06-05 2001-12-13 Benito Arranz Sanjuan Sildenafilo y nicotina, asociacion sinergica para las enfermedades neurodegenerativas

Also Published As

Publication number Publication date
DE69304955D1 (de) 1996-10-31
EP0559413A1 (en) 1993-09-08
DK0559413T3 (enExample) 1997-03-10
DE69304955T2 (de) 1997-04-10
GR3022072T3 (en) 1997-03-31
JPH0624983A (ja) 1994-02-01
ATE143263T1 (de) 1996-10-15
EP0559413B1 (en) 1996-09-25
US5212188A (en) 1993-05-18

Similar Documents

Publication Publication Date Title
DK0559413T3 (enExample)
TW249226B (enExample)
DE69326496D1 (de) Ringförmige Röntgenstrahlenquelle
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
SE9100920D0 (sv) New active compounds
ES2089136T3 (es) Tratamiento de enfermedades inflamatorias con la ayuda de derivados 15-ceto-prostaglandinas.
ATE125704T1 (de) Behandlung neurodegenerativer erkrankungen.
NO973581D0 (no) Fremgangsmåte for fremstilling av mono-N-substituerte tetraazamakrosykliske forbindelser
ES2085898T3 (es) Tratamiento de la enfermedad hepatobiliar con compuestos 15-cetoprostaglandina.
IT1271567B (it) Procedimento per l'ulteriore trattamento di salcicce
ES2113345T3 (es) Tratamiento de la disfuncion cardiaca con la ayuda de compuestos 15-ceto-prostaglandina.
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
EE03437B1 (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
ES2098325T3 (es) Tratamiento de cataratas con compuestos de prostaciclina.
AU5018893A (en) Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
NO921003L (no) Forbindelser for behandling av leukotrien-relaterte sykdommer
IT8867714A0 (it) Procedimento per il trattamento di fanghi di verniciatura
FI924616A0 (fi) Potilassänky

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 559413

Country of ref document: ES